:: Volume 10, Issue 4 (Autumn 2022) ::
Shefaye Khatam 2022, 10(4): 71-76 Back to browse issues page
A case of Guillain-Barré syndrome following COVID-19 infection
Negar Farhoudi , Nima Javanshir * , Mohammad Negaresh
Ardabil university of medical sciences , Nimajvn95@gmail.com
Abstract:   (879 Views)
Introduction: The Covid-19 pandemic started in December 2019 and revealed various symptoms and complications, including neurological complications. Recently studies have suggested a possible link between this viral infection and Guillain-Barré syndrome (GBS). Case Description: In this report, we present a patient who after being diagnosed with Covid-19 disease, suffers from ascending peripheral neuropathy. Various diagnostic procedures support the diagnosis of GBS. Results: After treatment with plasmapheresis, an acceptable response to treatment was observed. Conclusion: Given the viral nature of COVID-19 disease and the evidence of GBS association with viral diseases, as well as the possibility of disease invasion to the respiratory system, if neurological symptoms begin in a COVID-19 patient, GBS should be included in the differential diagnosis.
Keywords: Guillain-Barre Syndrome, COVID-19, Polyradiculoneuropathy
Full-Text [PDF 793 kb]   (1205 Downloads)    
Type of Study: Case Report --- Open Access, CC-BY-NC | Subject: Neurology
References
1. Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections. 2020; 9(1): 221-36. [DOI:10.1080/22221751.2020.1719902]
2. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. The Lancet Neurology. 2020. [DOI:10.2139/ssrn.3589350]
3. Yuki N, Hartung H-P. Guillain-Barré syndrome. New England Journal of Medicine. 2012; 366(24): 2294-304. [DOI:10.1056/NEJMra1114525]
4. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proceedings of the National Academy of Sciences. 2004; 101(31): 11404-9. [DOI:10.1073/pnas.0402391101]
5. van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994; 45(3): 114-22.
6. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2016(10). [DOI:10.1002/14651858.CD001446.pub5]
7. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology. 2008; 7(10): 939-50. [DOI:10.1016/S1474-4422(08)70215-1]
8. Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID‐19-associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & nerve. 2020; 62(4): 485-91. [DOI:10.1002/mus.27024]



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 10, Issue 4 (Autumn 2022) Back to browse issues page